A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia
A phase 1/2 trial of AK117 and Azacitidine in acute myeloid leukaemia, run by Akeso, active and no longer recruiting.
Overview
A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT04980885 by Akeso, with 68 participants enrolled, started 2021-08-13 and due to reach its primary completion in 2025-09. Interventions recorded: AK117 and Azacitidine.
Similar pages
not linked directly; found by shared links- TrialA Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
- TrialA Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
- TrialA Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
- TrialA Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
- TrialA Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
- TrialAn Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
- TrialA Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
- TrialA Study of BGB-11417 in Participants With Myeloid Malignancies
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.